Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Adeia Inc. has appointed Dipti Vachani as its new Chief Executive Officer and a member of the Board, effective October 12, 2026. She succeeds Paul E. Davis, who resigned to focus on health and personal pursuits but will remain as a consultant through the end of 2026 to ensure a smooth transition. Ms. Vachani joins the company with nearly 30 years of semiconductor industry experience, most recently serving as a senior executive at Arm Limited.
Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M
Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.
MediciNova, Inc. entered into a first amendment to its office lease with Newport Gateway Office LLC to extend the lease term for its principal executive offices. The amendment extends the expiration date from January 31, 2027, to April 30, 2030, and includes scheduled rent increases beginning in February 2027.
Beazer Homes USA Signs $350M M&A Deal with Dream Finders Homes, Inc.
Beazer Homes USA issued a conditional notice to redeem $350.0 million of its 7.250% Senior Notes due 2029. The redemption is contingent upon the closing of its previously announced merger with Dream Finders Homes, Inc., which is expected to occur on October 20, 2026. This filing provides a status and timeline update on the pending acquisition of Beazer Homes by Dream Finders Homes.
SkinHealth Systems stockholders approved an amendment to the company's Restated Certificate of Incorporation to implement a reverse stock split of its Class A Common Stock. The approved ratio range is between 1-for-5 and 1-for-20, with the final ratio to be determined by the board of directors.
Humacyte, Inc. appointed life science industry veterans Scott Coward and Paul Kuznik to its Board of Directors, effective September 22, 2026. Coward, a former executive at Exact Sciences, and Kuznik, a former CEO of Bolton Medical, bring extensive experience in commercialization and global operations as the company prepares for the planned launch of its ATEV product in dialysis access.
Grayscale Bittensor Trust (TAO) issued 151,900 shares in private placement transactions to accredited investors, raising approximately $0.89 million. The shares were issued at varying prices based on the Trust's Net Asset Value (NAV) per share in exchange for 2,869.42 TAO tokens. As of September 28, 2026, the Trust has a total of 2,994,200 shares issued and outstanding.
iQSTEL Inc. entered into an amendment to its acquisition agreement for GlobeTopper, LLC to settle a $500,000 purchase price obligation in cash rather than restricted common stock. The payment will be made in installments through early 2027 and is secured by the 51% membership interest in GlobeTopper originally acquired in 2025.
Phio Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 28, 2026, where shareholders elected six directors and ratified Grant Thornton, LLP as the independent auditor. Stockholders also approved an amendment to the 2020 Long Term Incentive Plan, increasing the number of shares available for issuance by 1,500,000 shares.
Scynexis Wins $214M Contract from Biomedical Advanced Research and Development Authority
SCYNEXIS was awarded a contract from BARDA providing up to $214 million in non-dilutive funding to support the development of SCY-247, a second-generation antifungal candidate. The agreement includes an initial $18.5 million base period to advance the candidate into Phase 2 studies for invasive candidiasis, with subsequent options that could fund the program through NDA submission.
Value
$214M
Counterparty
Biomedical Advanced Research and Development Authority (BARDA)
Term
up to 10 years
“We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
“While we remain focused on SCY-770, our new product candidate for ADPKD, this partnership enables the development of a novel therapy for the treatment and prevention of serious invasive fungal infections while leveraging our existing infrastructure and capabilities.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
Par Pacific Holdings announced that Jerry Stumbo, formerly of Valero Energy, has been appointed Executive Vice President – Refining and Logistics effective September 28, 2026. He succeeds Richard Creamer, who will transition to a Senior Advisor role until his planned retirement on April 1, 2027.
Gossamer Bio has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving a deficiency notice originally received on April 8, 2026. The company achieved compliance following a 1-for-80 reverse stock split that became effective on September 10, 2026, and the matter is now closed.
ADARx Pharmaceuticals closed its initial public offering (IPO) of 26,250,000 shares and a concurrent private placement of 5,255,542 shares to AbbVie Inc., both priced at $17.00 per share. The combined transactions generated approximately $535.6 million in gross proceeds, with AbbVie acquiring a 4.9% stake in the company.
Donna A. Henderson, Vice President and Chief Accounting Officer of Archrock, Inc., has notified the company of her intention to retire. Her retirement is scheduled to become effective on December 4, 2026.
F&M Bank Corp. approved amendments to its 2020 Stock Incentive Plan and 2023 Directors Stock Incentive Plan to increase the number of shares available for issuance. The 2020 Plan's share pool was increased from 200,000 to 500,000 shares, while the 2023 Plan's pool was increased from 25,000 to 100,000 shares. Additionally, Michael W. Pugh retired from the Board of Directors effective September 24, 2026, after reaching the mandatory retirement age.
M&T Bank Corporation is implementing changes and reclassifications to its financial statement presentation effective for the third quarter of 2026, including updates to 'Other income' categories and the separate presentation of loans held for sale. The company provided unaudited supplemental historical financial information to conform prior periods to this new presentation, noting that these changes have no impact on total net income or earnings per share.
Crestline Lending Solutions, LLC declared a regular cash distribution of approximately $0.52 per share, totaling $10.71 million. The distribution is payable on November 16, 2026, to shareholders of record as of September 30, 2026.
Ark Restaurants Chairman & CEO Michael Lawrence Weinstein Sells $808K of Stock
Michael Lawrence Weinstein, Chairman & CEO, sold 176,701 shares of Ark Restaurants Corp at $4.57 a share, worth $808K in total on Sep 24, 2026. Shares held after the trade: 856,111 (-17.1%).
Exascale Labs Holdings M&A Deal with Exascale Labs Inc.
Exascale Labs Holdings Inc. (formerly D. Boral ARC Merger Corporation) filed this amendment to provide required financial statements following the completion of its business combination with Exascale Labs Inc. The merger was consummated on August 27, 2026, resulting in Exascale Labs Inc. becoming a subsidiary of the public entity. This filing includes audited financial statements for Exascale Labs for the fiscal years ended June 30, 2026 and 2025.
Sturm Ruger & Co VP of New Product Development Michael W. Wilson Sells $25.2K of Stock
Michael W. Wilson, VP of New Product Development, sold 600 shares of Sturm Ruger & Co Inc at $41.95 a share, worth $25.2K in total on Sep 24, 2026. Shares held after the trade: 628 (-48.9%).
Highwater Ethanol's Board of Directors approved amendments to the 2026 Executive Bonus Plan for its CEO and CFO. The new terms provide additional bonus eligibility based on the company achieving net income over $10 million and receiving Section 45Z federal clean fuel production tax credits, allowing the CEO and CFO to earn annual bonuses up to 59% and 56% of their base salaries, respectively.
Marygold Companies M&A Deal with Madison Dearborn Partners, LLC
The Marygold Companies (MGLD) entered into a definitive agreement to be acquired by funds managed by Madison Dearborn Partners (MDP) for $2.00 per share in cash. The transaction, which represents a 100% premium over the company's unaffected closing price, will result in Marygold becoming a privately held company. Following the merger, MDP plans to refocus the business on its USCF subsidiary, a commodity-focused ETF manager with approximately $6 billion in assets under management.
Friedman Industries held its 2026 Annual Meeting of Shareholders on September 22, 2026, where shareholders elected six directors and ratified Baker Tilly US, LLP as the independent auditor for fiscal 2027. Shareholders also approved executive compensation in a non-binding advisory vote, but a proposed amendment to the Articles of Incorporation to allow shareholders to amend Bylaws failed to receive the required two-thirds majority.
New Mountain Private Credit Fund declared a regular monthly distribution of $0.19 per share for September 2026, payable on October 30 to shareholders of record as of September 30. The company also reported an August 31, 2026, net asset value (NAV) of $22.84 per share and an aggregate NAV of approximately $949.4 million.
Zumiez President International Adam Christopher Ellis Buys $134K of Stock
Adam Christopher Ellis, President International, bought 10,000 shares of Zumiez Inc at $13.40 a share, worth $134K in total on Sep 18, 2026. Shares held after the trade: 83,664 (+13.6%).
Coastal Financial Corporation's fintech partner, Bluevine, Inc., has entered into a definitive agreement to be acquired by Valley National Bancorp. Coastal Community Bank currently holds approximately $447 million in Bluevine-related deposits, but management does not expect the transaction to have a material adverse effect on the company's liquidity or funding profile due to its diversified partner platform.
CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus small bowel capsule endoscopy system. The tool is designed to reduce physician review time by automatically identifying and prioritizing images containing suspected abnormal lesions in patients with suspected small bowel bleeding.
World Gold Trust Services, LLC, the sponsor of SPDR Gold Trust, appointed Joan A. Binstock to its Board of Directors and Audit Committee effective September 28, 2026. Ms. Binstock is a veteran financial executive who previously served as CFO of Lord, Abbett & Co. and COO of Morgan Grenfell Asset Management.
World Gold Trust's sponsor, WGC USA Asset Management Company, LLC, has appointed Joan A. Binstock to its Board of Directors and Audit Committee, effective September 28, 2026. Ms. Binstock is a former CFO of Lord, Abbett & Co. and currently serves on several boards, including Morgan Stanley Direct Lending Fund and KKR Real Estate Select Trust.